Radionuclide therapy of neuroendocrine tumors

Andrew Mallia; Marco Maccauro; Ettore Seregni; Chiara Bampo; Carlo Chiesa; Emilio Bombardieri

doi:10.1007/978-1-4614-4021-5_4

Radionuclide therapy of neuroendocrine tumors

Andrew Mallia, Marco Maccauro, Ettore Seregni, Chiara Bampo, Carlo Chiesa, Emilio Bombardieri

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Neuroendocrine tumors (NETs) are a group of tumors which frequently express somatostatin receptors (SSTRs) and represent 1 % of all neoplasms that may arise in the body. NETs of the gastro-entero-pancreatic tract (GEP NETs) and tumors of the sympatho-adrenal lineage are the most frequent tumors observed in clinical practice. Improved diagnostic techniques, both functional and anatomical, have resulted in an increased incidence of NETs. The term neuroendocrine defines cells that share common characteristics, such as the ability to take up and decarboxylate several amine precursors (APUD system), the absence of axons and synapses, the production of cell type-specific hormonal products and the demonstration of particular histopathological staining [1]. The variation in biological characteristics of these tumors poses considerable problems when deciding the optimal treatment strategies.

Original language	English
Title of host publication	Nuclear Medicine Therapy: Principles and Clinical Applications
Publisher	Springer New York
Pages	57-83
Number of pages	27
ISBN (Print)	9781461440215, 1461440203, 9781461440208
DOIs	https://doi.org/10.1007/978-1-4614-4021-5_4
Publication status	Published - Aug 1 2013

ASJC Scopus subject areas

Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1007/978-1-4614-4021-5_4

Cite this

@inbook{c4456b0d0fad4a2e872e7d59f2cc000f,

title = "Radionuclide therapy of neuroendocrine tumors",

abstract = "Neuroendocrine tumors (NETs) are a group of tumors which frequently express somatostatin receptors (SSTRs) and represent 1 % of all neoplasms that may arise in the body. NETs of the gastro-entero-pancreatic tract (GEP NETs) and tumors of the sympatho-adrenal lineage are the most frequent tumors observed in clinical practice. Improved diagnostic techniques, both functional and anatomical, have resulted in an increased incidence of NETs. The term neuroendocrine defines cells that share common characteristics, such as the ability to take up and decarboxylate several amine precursors (APUD system), the absence of axons and synapses, the production of cell type-specific hormonal products and the demonstration of particular histopathological staining [1]. The variation in biological characteristics of these tumors poses considerable problems when deciding the optimal treatment strategies.",

author = "Andrew Mallia and Marco Maccauro and Ettore Seregni and Chiara Bampo and Carlo Chiesa and Emilio Bombardieri",

year = "2013",

month = aug,

day = "1",

doi = "10.1007/978-1-4614-4021-5_4",

language = "English",

isbn = "9781461440215",

pages = "57--83",

booktitle = "Nuclear Medicine Therapy: Principles and Clinical Applications",

publisher = "Springer New York",

}

TY - CHAP

T1 - Radionuclide therapy of neuroendocrine tumors

AU - Mallia, Andrew

AU - Maccauro, Marco

AU - Seregni, Ettore

AU - Bampo, Chiara

AU - Chiesa, Carlo

AU - Bombardieri, Emilio

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Neuroendocrine tumors (NETs) are a group of tumors which frequently express somatostatin receptors (SSTRs) and represent 1 % of all neoplasms that may arise in the body. NETs of the gastro-entero-pancreatic tract (GEP NETs) and tumors of the sympatho-adrenal lineage are the most frequent tumors observed in clinical practice. Improved diagnostic techniques, both functional and anatomical, have resulted in an increased incidence of NETs. The term neuroendocrine defines cells that share common characteristics, such as the ability to take up and decarboxylate several amine precursors (APUD system), the absence of axons and synapses, the production of cell type-specific hormonal products and the demonstration of particular histopathological staining [1]. The variation in biological characteristics of these tumors poses considerable problems when deciding the optimal treatment strategies.

AB - Neuroendocrine tumors (NETs) are a group of tumors which frequently express somatostatin receptors (SSTRs) and represent 1 % of all neoplasms that may arise in the body. NETs of the gastro-entero-pancreatic tract (GEP NETs) and tumors of the sympatho-adrenal lineage are the most frequent tumors observed in clinical practice. Improved diagnostic techniques, both functional and anatomical, have resulted in an increased incidence of NETs. The term neuroendocrine defines cells that share common characteristics, such as the ability to take up and decarboxylate several amine precursors (APUD system), the absence of axons and synapses, the production of cell type-specific hormonal products and the demonstration of particular histopathological staining [1]. The variation in biological characteristics of these tumors poses considerable problems when deciding the optimal treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=84929545996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929545996&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4021-5_4

DO - 10.1007/978-1-4614-4021-5_4

M3 - Chapter

AN - SCOPUS:84929545996

SN - 9781461440215

SN - 1461440203

SN - 9781461440208

SP - 57

EP - 83

BT - Nuclear Medicine Therapy: Principles and Clinical Applications

PB - Springer New York

ER -

Radionuclide therapy of neuroendocrine tumors

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this